Profile data is unavailable for this security.
About the company
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Company’s product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
- Revenue in TWD (TTM)61.41m
- Net income in TWD-2.14bn
- Incorporated2013
- Employees--
- LocationTanvex BioPharma IncFloor 4, Willow House, Cricket Square,P O BOX 2804GRAND CAYMAN KY1-1112Cayman IslandsCYM
- Websitehttp://www.tanvex.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinphar Pharmaceutical Co Ltd | 2.96bn | 375.17m | 6.06bn | 984.00 | 16.19 | 1.96 | 10.38 | 2.05 | 2.23 | 2.23 | 17.64 | 18.47 | 0.4765 | 2.37 | 6.03 | -- | 5.74 | -0.0147 | 7.76 | -0.0203 | 36.83 | 37.49 | 12.04 | -0.0344 | 1.50 | 16.24 | 0.364 | 79.70 | 3.72 | 5.98 | 67.01 | 111.88 | 3.31 | 58.49 |
| China Chemical & Pharmaceutical Co Ltd | 8.57bn | 322.29m | 6.63bn | 1.40k | 20.61 | 0.8899 | 10.43 | 0.7735 | 1.08 | 1.08 | 28.71 | 25.00 | 0.6676 | 2.15 | 5.14 | -- | 2.52 | 3.69 | 3.42 | 4.96 | 36.62 | 36.56 | 3.77 | 5.50 | 0.8837 | -- | 0.3152 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
| Tanvex Biopharma Inc | 61.41m | -2.14bn | 6.92bn | -- | -- | 6.96 | -- | 112.71 | -16.51 | -16.51 | 0.4711 | 6.06 | 0.0199 | 0.0123 | 12.62 | -- | -69.13 | -49.24 | -77.48 | -53.18 | 97.22 | 49.20 | -3,480.00 | -10,835.34 | 1.36 | -77.72 | 0.6784 | -- | 174.11 | -- | -30.22 | -- | -8.09 | -- |
| Panion & BF Biotech Inc | 1.88bn | 77.22m | 8.18bn | 321.00 | 105.99 | 4.28 | 33.03 | 4.35 | 0.9001 | 0.9001 | 21.94 | 22.29 | 0.5947 | 1.67 | 8.19 | -- | 2.44 | 4.08 | 3.55 | 5.63 | 51.78 | 52.37 | 4.10 | 5.93 | 0.8931 | 16.24 | 0.2758 | 111.06 | -21.54 | 5.96 | -57.65 | -13.47 | 35.39 | -3.23 |
| Pell Bio Med Technology Co Ltd | 18.03m | -398.76m | 8.42bn | -- | -- | 6.79 | -- | 467.19 | -8.62 | -8.62 | 0.3898 | 21.71 | 0.0147 | 10.59 | 2.64 | -- | -32.59 | -- | -35.02 | -- | -144.96 | -- | -2,225.03 | -- | 12.58 | -- | 0.1275 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
Data as of May 15 2024. Currency figures normalised to Tanvex BioPharma Inc's reporting currency: Taiwan Dollar TWD
0.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 104.00k | 0.07% |
| The Vanguard Group, Inc.as of 31 Jan 2023 | 4.08k | 0.00% |
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
